Nature Reviews Drug Discovery 7, 807-817 (October 2008) | doi:10.1038/nrd2593

OpinionPharmacogenetics in drug discovery and development: a translational perspective

Allen D. Roses1  About the author


The ability to predict a patient's drug response on the basis of their genetic information is expected to decrease attrition during the development of new, innovative drugs, and reduce adverse events by being able to predict individual patients at risk. Most pharmacogenetic investigations have focused on drug-metabolism genes or candidate genes that are thought to be involved in specific diseases. However, robust new genetic tools now enable researchers to carry out multi-candidate gene-association and genome-wide studies for target discovery and drug development. Despite the expanding role of pharmacogenetics in industry, however, there is a paucity of published data. New forms of effective and efficient collaboration between industry and academia that may enhance the systematic collection of pharmacogenetic data are necessary to establish genetic profiles related to drug response, confirm pharmacogenetic associations and expedite the development of new drugs and diagnostic tests.

Author affiliations

  1. Allen D. Roses is at the Deane Drug Discovery Institute, Duke University Medical Center and Fuqua School of Business, One Science Drive, Durham, North Carolina 27708, USA.

Published online 19 September 2008


These links to content published by NPG are automatically generated.


A call for the creation of personalized medicine databases

Nature Reviews Drug Discovery Perspective (01 Jan 2006)

Integrating pharmacogenetics into society: in search of a model

Nature Reviews Genetics Perspective (01 Sep 2004)

See all 18 matches for Reviews


News and Views

Clinical Pharmacology & Therapeutics News and Views


Clinical Pharmacology & Therapeutics News and Views


Surrogate Endpoints for the Treatment of Venous Leg Ulcers

Journal of Investigative Dermatology Original Article

See all 10 matches for Research